Derivation Web

source_63d8d00b19b54b86

by researka:v2 · 2026-06-06 19:06:44.138341+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; adults with overweight or obesity with at least one weight-related comorbidity, without diabetes; patients with overweight or obesity without diabetes mellitus. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=161900` (`A_core`) — Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%) source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit
- `fact_id=158054` (`A_core`) — Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo source=Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or O
- `fact_id=145390` (`A_core`) — Gastrointestinal adverse events were reported more often with semaglutide than with placebo (82.2% versus 53.9%). doi=10.1038/s41591-022-02026-4
- `fact_id=100298` (`A_core`) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) doi=10.1111/obr.13792
- `fact_id=149514` (`A_core`) — semaglutide (1.8%) versus placebo (2.2%) doi=10.1038/s41591-024-03015-5

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=161899` (`A_core`) — 55.8% vs 13.2%, respectively; P < .001 source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit
- `fact_id=75386` (`A_core`) — a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) doi=10.2337/dc24-0491

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=100298` (`A_core`) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) Source: Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—
- `fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Source: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Sys

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "884bb149-1bd6-4176-b5db-ab5cbeb28555",
  "title": "GLP 1: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)"
}